Rafivirumab

Rafivirumab is a monoclonal antibody designed for the treatment of cancer. It was developed by Eli Lilly and Company.

Mechanism of action

Rafivirumab works by inhibiting the vascular endothelial growth factor receptor 2 (VEGFR2), which is involved in the growth and development of new blood vessels. By blocking this receptor, rafivirumab can help to slow the growth of tumors.

Clinical trials

Rafivirumab has been studied in several clinical trials for various types of cancer, including colorectal cancer, lung cancer, and gastric cancer. However, the results have been mixed, and the drug is not currently approved for use in any country.

Side effects

Like all drugs, rafivirumab can cause side effects. The most common side effects reported in clinical trials include fatigue, diarrhea, and high blood pressure. In some cases, rafivirumab can also cause more serious side effects, such as bleeding, blood clots, and heart problems.

See also

• Monoclonal antibodies for cancer
• VEGF inhibitors
• Eli Lilly and Company

References

Rafivirumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski